Anthropometric, metabolic and bone changes in women with premature ovarian failure when using estradiol analogues
Abstract
Abstract. Goal. To compare changes in bone, metabolic and anthropometric parameters in young women with hypergonadotropic amenorrhea (premature ovarian failure [POF], complete androgen insensitivity syndrome [CAIS] with removed gonads), undergoing various HT (transdermal estradiol [TE], oral estradiol valerate [OEV], oral Ethinyl estradiol [OEE] with or without progestin) or without therapy. Methods. A pilot cohort study based on prospectively collected data. Bone density, body composition, and anthropometric parameters were assessed in 40 young women. Results. At time t0, only 5% of patients had normal bone mineral density (BMD) in all bone regions, while 75% and 20% had osteopenia or osteoporosis, respectively, in at least one bone region. Control densitometry (t1) was performed 22.1 ± 9.2 months later. Lumbar and femoral BMD increased over time in the treatment groups with a significant time-treatment interaction effect (p = 0.004 and p = 0.025, respectively). Conclusions. These preliminary data suggest that estradiol is administered both transdermally and orally in young women with hypergonadotropic amenorrhea.